中国基础胰岛素临床应用现状、展望及其周制剂研发进展  

Basal insulin in China:Current status and update on weekly preparation

作　　者：李健[1] 杨琨[1] 洪天配[1] Li Jian;Yang Kun;Hong Tianpei(Department of Endocrinology and Metabolism,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院内分泌科,北京100191

出　　处：《中华内分泌代谢杂志》2024年第11期989-993,共5页Chinese Journal of Endocrinology and Metabolism

摘　　要：基础胰岛素治疗是血糖管理的基石, 但我国基础胰岛素应用存在起始晚、起始剂量偏低、剂量调整不积极等问题, 难以发挥其理想的降糖效果。有鉴于此, BEYOND系列研究应势开展, 为优化中国基础胰岛素临床实践提供循证依据。此外, 基础胰岛素即将进入周制剂时代, Ⅲ期临床试验结果证实基础胰岛素周制剂具有良好的疗效和安全性, 其注射频率少等优势将为克服我国基础胰岛素的应用困境带来新希望。Basal insulin is essential for blood glucose management.However,its clinical application in China faces multiple challenges such as delayed initiation,low initial dosage,and inadequate dose adjustments.The BEYOND series of studies were conducted to provide an evidence-based basis for optimizing basal insulin use in China.Moreover,basal insulin is advancing towards weekly preparation.Phase II clinical trials have demonstrated that weekly basal insulin is both effective and safe,and its reduced injection frequency may help address the challenges associated with basal insulin use in China.

关 键 词：基础胰岛素 临床实践 周制剂 依从性 糖尿病 

分 类 号：R587.1[医药卫生—内分泌]